Wockhardt — Q4 FY25 earnings call

Call held 5 Jun 2025

Management summary

Wockhardt has successfully transitioned from a generic-focused firm to a research-driven organization, with its NCE (New Chemical Entity) portfolio nearing commercialization. The company significantly strengthened its balance sheet through a ₹1,000 crore QIP, bringing net debt down to near-zero levels. Management is now focused on the global launch of ZAYNICH and expanding its biosimilar capacity to capitalize on market gaps left by competitors like Novo Nordisk.

Highlights

  • Annual Revenue reached ₹3,033 crores, representing a 5% YoY growth.

  • EBITDA grew significantly by 67% to approximately ₹418 crores.

  • EBITDA margin expanded by 500 basis points, rising from 9% to 14%.

  • Net debt drastically reduced to ₹64 crores from ₹882 crores in FY22, aided by a ₹1,000 crore QIP.

  • Research-driven businesses now contribute 18% of total sales turnover.

  • ZAYNICH (WCK 5222) completed Global Phase 3 trials with 20% superiority over existing treatments.

  • India addressable market for ZAYNICH estimated at ₹17,000 crores; Miqnaf at ₹10,800 crores.

  • Biosimilar business grew by 20% during the year.

Key financials

  1. Revenue ₹3,033 Cr +5%YoY
  2. EBITDA ₹418 Cr +67%YoY
  3. EBITDA Margin 14%
  4. Net Debt ₹64 Cr -92.7%YoY
  5. Equity ₹4,600 Cr +27.7%YoY

What they filed

Q1 FY27: revenue up 35.8%, net profit up 55.1% against the same quarter last year.

₹ Cr · quarterly
Line itemQ2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26Q4 FY26Q1 FY27
Revenue370 325 355 413 380 +3%430 +32%516 +45%561 +36%
EBITDA49 62 106 131 113 +131%113 +82%161 +52%158 +21%
Net profit-36 -22 40 69 54 +250%28 +227%167 +318%107 +55%
How to read this

₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.

Segment breakdown

  • Emerging Markets
    10% Revenue Growth
  • UK
    8% Revenue Growth
  • India Branded
    4% Revenue Growth
  • Biosimilar
    20% Revenue Growth

Guidance & targets

Capacity

  • Biosimilar Capacity Capacity · next 24 to 36 months · High confidence Double current capacity
    we are also ramping up our capacities and in fact doubling -- want to double our capacities over the next 24 months and put up new facility

    — Dr. Murtaza Khorakiwala, Managing Director

Revenue

  • Biosimilar Business Size Revenue · next 3 years · Medium confidence Double current business
    we expect to double the business in the next 3 years.

    — Dr. Murtaza Khorakiwala, Managing Director

  • ZAYNICH India Sales Revenue · first 6 to 9 months of launch · Medium confidence ₹200-400 crore
    And we hope that we access this market within first 6 to 9 months and even if we get 20-30,000 patients we are looking at something like INR200 crore, INR300 crore, INR400 crore sales.

    — Dr. Habil Khorakiwala, Founder Chairman

Volume

  • ZAYNICH Patient Potential Volume · next 3 years · Medium confidence 80,000-100,000 patients
    But I think in 3 years we should be looking at 80-100,000 patient potential for ZAYNICH.

    — Dr. Habil Khorakiwala, Founder Chairman

Risks & concerns

  • Regulatory Approval Timelines

    medium

    The USFDA approval process typically takes 9-12 months; any hurdles could delay the '26-'27 launch target.

    Analyst acknowledged

  • Commercialization Execution

    medium

    Management admitted a 'learning curve' with their previous launch (EMROK) and is hiring multinational talent to avoid repeat issues.

    Management acknowledged

  • Pricing and Geopolitical Impact

    low

    Analyst raised concerns about Trump's policies impacting $8,000-$10,000 per patient pricing; management focused on the clinical value proposition instead.

    Analyst downplayed

Areas of evasion (1)

  • Specific out-licensing income and royalty percentage projections.

Q&A highlights

3 direct
ZAYNICH US Commercialization Strategy Direct
One option, we are seriously thinking to create our own organization... Second option, we are simultaneously looking to out license the product with some of the big pharma or any suitor.

Reveals management's dual-track approach to maximize value in the US market, either through high-margin self-marketing or a lucrative licensing deal.

Asked by Unknown Analyst

Future Fundraising and Equity Dilution Direct
I think subsequent here with the launch of NCE, we will have much better cash flow. So we believe mostly this cash flow coming in would be more than adequate for research.

Management signals that further equity dilution is unlikely as NCE commercialization is expected to fund future R&D requirements.

Asked by Bharat Sheth

ZAYNICH Awareness and Adoption Timeline Direct
we don't expect years to get into a doctor to appreciate, we expect doctor to appreciate this molecule very short time... we would be going very quickly to almost all doctors ZAYNICH by multi-channel approach.

Clarifies that adoption will be rapid due to the high unmet need and a targeted medical-representative-heavy sales force (1:4 ratio).

Asked by Dhruvesh Sanghvi

2 min read 5 chapters

Detailed narrative

NCE Portfolio: From Discovery to Commercialization

Wockhardt is transitioning into a research-driven organization, with its NCE portfolio now contributing 18% of sales. The flagship molecule, ZAYNICH (WCK 5222), has completed Global Phase 3 trials showing 20% superiority over existing treatments. The company has already saved 51 lives through compassionate use, validating the drug's efficacy against resistant organisms in real-world scenarios. Management expects to file for USFDA approval in the coming quarter, targeting a US launch by mid-2026.

Financial De-leveraging and Capital Structure

The company has undergone a massive balance sheet cleanup, reducing net debt from ₹882 crores in FY22 to just ₹64 crores in FY25. This was significantly aided by a ₹1,000 crore QIP conducted during the year. With cash reserves of approximately ₹600 crores and equity increasing to ₹4,600 crores, management believes current cash flows will be sufficient to fund the ongoing USD 200-250 million annual R&D spend without further significant dilution.

Strategic Pivot in Biosimilars

Wockhardt is aggressively expanding its diabetes biosimilar business, which grew by 20% last year. The company plans to double its manufacturing capacity over the next 24-36 months to capitalize on a $1.5 billion emerging market opportunity. A key catalyst is Novo Nordisk's decision to discontinue disposable insulin pens, which management believes opens up a ₹450 crore market in India and $157 million in emerging markets for existing players.

Operational Excellence and Margin Expansion

EBITDA margins expanded by 500 basis points to 14% due to a rigorous focus on cost reduction and operational excellence. The company restructured manufacturing from external to internal sources and implemented energy cost reduction measures. These initiatives, combined with a 67% growth in EBITDA, have placed the company in a much healthier financial position compared to the previous year.

ZAYNICH Global Market Opportunity

Management has modeled a global addressable market of 2 million patients for ZAYNICH, including 158,000 in the US and 1 million in India. The potential target addressable market (TAM) is valued at $7 billion globally and ₹17,000 crores in India. To capture this, Wockhardt is building a specialized sales force with a high ratio of medical doctors to representatives (1:4 or 1:5) to effectively communicate the scientific superiority of the molecule to hospital specialists.

This is an AI-generated summary of a publicly available earnings call transcript.
View original transcript

More Healthcare earnings calls